Prophylaxis against cytomegalovirus infection in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation

dc.contributor.authorFerres, Marcela
dc.contributor.authorNervi, Bruno
dc.contributor.authorRamirez, Pablo
dc.date.accessioned2024-01-10T13:16:46Z
dc.date.available2024-01-10T13:16:46Z
dc.date.issued2012
dc.description.abstractCMV is one of the main infectious problems for SOT and HSCT. The severity of the complications are mainly associated with the type of transplant and immune status against the virus of the transplant donor and the transplant recipient. It is important to prevent exposure, using safe blood transfusion CMV seronegative donors (B1) and/or use of blood leucocytes-depleted by filtration (A1). In addition to preventing exposure, there are two widely used prevention strategies: universal prophylaxis with antiviral therapy or "pre-emptive" strategy based on the use of antivirals only to the early detection of CMV replication in blood. The first option is most used in the SOT management, especially for those identified as the high risk group of CMV disease: R (+), with D (+) or D (-) (A1), where the recommended drug is ganciclovir or valganciclovir. The second approach is preferable for HSCT, which recommends weekly monitoring for CMV viral load from day 10 to 100 post transplant (A3). This strategy requires having a viral laboratory support (A2). The selected antiviral in the case of pre emptive therapy is intravenous ganciclovir (A1).
dc.fechaingreso.objetodigital2024-05-30
dc.format.extent6 páginas
dc.fuente.origenWOS
dc.identifier.doi10.4067/S0716-10182012000500004
dc.identifier.eissn0717-6341
dc.identifier.issn0716-1018
dc.identifier.pubmedidMEDLINE:23282552
dc.identifier.urihttps://doi.org/10.4067/S0716-10182012000500004
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78611
dc.identifier.wosidWOS:000310561600004
dc.information.autorucMedicina;Ferres M;S/I;66180
dc.information.autorucMedicina;Nervi B;S/I;604
dc.information.autorucMedicina;Ramirez P;S/I;1242
dc.language.isoes
dc.nota.accesoContenido completo
dc.pagina.final28
dc.pagina.inicio23
dc.publisherSOC CHILENA INFECTOLOGIA
dc.revistaREVISTA CHILENA DE INFECTOLOGIA
dc.rightsacceso abierto
dc.subjectCytomegalovirus
dc.subjectprophylaxis
dc.subjectganciclovir
dc.subjectvalganciclovir
dc.subjecttransplant
dc.subjectsolid organ transplantation
dc.subjecthematopoietic stem cells transplantation
dc.subjectPREEMPTIVE THERAPY
dc.subjectBLOOD-PRODUCTS
dc.subjectCMV INFECTION
dc.subjectDISEASE
dc.subjectVALGANCICLOVIR
dc.subjectPREVENTION
dc.subjectRECIPIENTS
dc.subjectRISK
dc.subjectSEROPREVALENCE
dc.subjectGANCICLOVIR
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleProphylaxis against cytomegalovirus infection in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation
dc.typeartículo
dc.volumen29
sipa.codpersvinculados66180
sipa.codpersvinculados604
sipa.codpersvinculados1242
sipa.indexWOS
sipa.indexScielo
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Prophylaxis against cytomegalovirus infection in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation.pdf
Size:
3.46 MB
Format:
Adobe Portable Document Format
Description: